Janux Therapeutics, Inc. (JANX)

januxtherapeutics jun09 lt

Janux Therapeutics, founded in 2017, will be making its debut on the Nasdaq Global Market today (June 11), under ticker symbol "JANX."

The La Jolla, California-based Janux Therapeutics is a preclinical biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology for metastatic castrate-resistant prostate cancer, colorectal cancer and other common cancers.

The company has offered to sell 11.4 million shares in the Initial Public Offering (IPO) at a price of $17 each. The underwriters have a 30-day option to purchase up to 1.71 million additional shares.

The aggregate gross proceeds are expected to be $193.8 million. The offering is scheduled to close on June 15, 2021.

Underwriters of the IPO:

BofA Securities, Inc., Cowen and Company, LLC and Evercore Group L.L.C., H.C. Wainwright & Co., LLC

Pipeline and Near-term Catalysts:

The company's drug candidates include PSMA-TRACTr, EGFR-?TRACTr and TROP2-TRACTr.

-- PSMA-TRACTr is for metastatic castrate-resistant prostate cancer (mCRPC), for which an IND is expected to be submitted in the first half of 2022.

-- EGFR-TRACTr, initially for the treatment of colorectal cancer, with the submission of IND planned for the second half of 2022.

--TROP2-TRACTr, initially for triple-negative breast cancer, for which IND submission is expected in 2023.

-- The company is also developing TRACIr costimulatory bispecific product candidate, designed to further enhance the anti-tumor activity of T cells, which is under discovery stage.

For comments and feedback contact: editorial@rttnews.com

Follow RTT